Progress in Systemic Lupus Erythematosus Research

PROGRESS IN SYSTEMIC LUPUSERYTHEMATOSUS RESEARCH......Page 3
NOTICE TO THE READER......Page 6
CONTENTS......Page 7
PREFACE......Page 9
ABSTRACT......Page 15
INTRODUCTION......Page 16
Results......Page 18
DISCUSSION......Page 19
REFERENCES......Page 20
FERTILITY......Page 23
INFLUENCE OF SLE ON PREGNANCY:OBSTETRIC AND FETAL OUTCOME......Page 24
NEONATAL LUPUS ERYTHEMATOSUS......Page 25
COSTICOSTEROIDS......Page 26
Cyclosporin A (Cs A)......Page 27
REFERENCES......Page 28
ABSTRACT......Page 31
SUBJECTS......Page 32
2. Blood Pressure......Page 33
4. Skin Temperature......Page 35
Peripheral Circulation......Page 38
REFERENCES......Page 40
ABSTRACT......Page 43
PERICARDITIS......Page 44
MYOCARDITIS......Page 47
Scintography......Page 48
Endomyocardial Biopsy......Page 49
Treatment of Myocarditis......Page 50
ATHEROSCLEROSIS IN SLE......Page 51
Hypertension and Smoking......Page 52
Corticosteroids......Page 53
TNF-&@945; and IL-1......Page 54
Autoantibodies......Page 55
Cohort Studies and Risk Factors for Atherosclerosis......Page 56
Coronary Angiography......Page 57
Intracoronary Ultrasonography......Page 58
Magnetic Resonance Coronary Angiography (MRCA) and Positron EmissionTomography......Page 59
Coronary Flow Reserve Evaluated by Doppler......Page 60
Antimalarial Drugs in Atherosclerosis......Page 61
Statins in SLE......Page 62
Treatment of Atherosclerotic Complications......Page 63
Definition......Page 64
Postmortem Studies......Page 65
Pathogenesis......Page 66
Diagnostic of PAH......Page 67
Color-Doppler Echocardiography......Page 68
Advances in the Treatment of Pulmonary Hypertension......Page 69
Left Ventricular Diastolic Dysfunction......Page 72
Diastolic Dysfunction in SLE......Page 73
Anti-Lamin B1 Autoantibodies as Major Determinant of Thromboprotectionin SLE Patients Displaying Antiphospholipid Antibodies......Page 74
aLB1 and Thromboprotection......Page 75
Autoantibodies and Cardiac Involvement......Page 76
VALVULAR ABNORMALITIES......Page 77
RHYTHM AND CONDUCTION TISSUEABNORMALITIES......Page 78
CONCLUSION......Page 79
REFERENCES......Page 80
ABSTRACT......Page 91
INTRODUCTION......Page 92
Risk factors for CVD in SLE......Page 93
Prevention and Treatment of CVD in SLE......Page 98
Non-Disease Related Risk Factors for Osteoporosis in SLE......Page 99
Disease Related Risk Factors for Osteoporosis in SLE......Page 100
Fractures in SLE......Page 101
Prevention and Treatment of Osteoporosis in SLE......Page 102
Risk Factors for Infections in SLE......Page 103
Deficiency of Mannose-Binding Lectin and Infections in SLE......Page 104
Diagnostic and Therapeutic Considerations......Page 105
REFERENCES......Page 106
ABSTRACT......Page 119
INTRODUCTION......Page 120
Experimental Design......Page 122
Proteinuria......Page 123
Measurement of Autoantibodies......Page 124
RNA EXTRACTION......Page 125
Skin Transplantation......Page 126
Severely Injured MRL/MpJ Mice Develop a “Lupus-Like” Syndrome......Page 127
Serum Hypergammaglobulinemia and Anti-DNA Antibodies......Page 130
Renal Histopathology......Page 131
Expression of Cytokine mRNA in Skin Post Burn Injury......Page 132
Skin Isograft Rejection......Page 134
CONCLUSION......Page 135
REFERENCES......Page 138
ABSTRACT......Page 145
RATIONALE FOR USING PEPTIDE-BASED IMMUNOTHERAPYIN AUTOIMMUNE DISEASE......Page 146
Peptide Selection......Page 148
Duration of Tolerance......Page 149
TYPES OF IMMUNOTHERAPEUTIC PEPTIDES......Page 150
OVERVIEW OF PEPTIDE IMMUNOTHERAPY IN AUTOIMMUNITY......Page 151
RATIONALE FOR USING IMMUNOTHERAPEUTICPEPTIDES IN SLE......Page 152
CONSIDERATIONS FOR PEPTIDE-BASEDIMMUNOTHERAPY OF SLE......Page 153
Peptides Eluted from MHC Molecules......Page 154
Peptides Recognized by T Cells from Both Lupus Mice and Patients......Page 155
pCons Peptide......Page 156
hCDR1 Peptide......Page 158
CONCLUSION......Page 159
REFERENCES......Page 160
ABSTRACT......Page 169
INTRODUCTION......Page 170
Anti-Neuronal Antibodies......Page 171
Anti-DNA Antibodies Cross-Reactive with NMDA Receptor......Page 174
CONCLUSION......Page 179
REFERENCES......Page 181
ABSTRACT......Page 191
INTRODUCTION......Page 192
Conditioning Regimen......Page 195
Supportive Care......Page 196
RESULTS......Page 197
Transplant-Related Mortality (Toxity)......Page 198
OVERALL AND DISEASE-FREE SURVIVAL......Page 199
CONCLUSION......Page 201
REFERENCES......Page 204
ABSTRACT......Page 207
INTRODUCTION......Page 208
MR Spectroscopy......Page 210
Diffusion Tensor Imaging......Page 213
Imaging Findings in SLE and NPSLE Using DWI and DTI......Page 217
REFERENCES......Page 219
ABSTRACT......Page 225
THE CONCEPT OF PERSONALIZED MEDICINE......Page 226
IMPLEMENTING PERSONALIZED MEDICINE IN SLE......Page 228
FUTURE DIRECTIONS......Page 233
CONCLUSION......Page 234
REFERENCE LIST......Page 235
ABSTRACT......Page 241
Epidemiology......Page 242
The Role of Endothelium......Page 243
COX/Metalloproteinases Role......Page 244
ANTIATHEROSCLEROTIC PROPERTIES OF STATINS......Page 245
PLEIOTROPIC PROPERTIES OF STATINS......Page 247
REFERENCES......Page 250
INDEX......Page 259